Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).-MedSci.cn

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Llovet, JM; Yen, CJ; Finn, RS; Kang, YK; Kudo, M; Galle, PR; Assenat, E; Pracht, M; Lim, HY; Rau, KM; Borg, C; Hiriart, JB; Daniele, B; Berg, T; Chung, HC; Godinot, N; Wang, C; Hsu, YZ; Schelman, WR; Zhu, AX

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务